Eli Lilly and Company
LLY Healthcare Drug Manufacturers - General NYSE
$1010.31
$-4.18 (-0.41%)
Open: $1023.84 | High: $1027.39 | Low: $1004.03 | Prev Close: $1014.49
Market Cap: $907.55B
Volume: 2.0M | Avg: 3.8M
Last updated: December 05, 2025 at 10:04 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 580
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 49.55 |
| P/B Ratio | 38.08 |
| P/S Ratio | 15.27 |
| EPS | $20.39 |
| Beta | 0.37 |
| Shares Outstanding | 898.29M |
| 52-Week High | $1111.99 |
| 52-Week Low | $623.78 |
| SMA 50 | $905.62 |
| SMA 200 | $811.25 |
| Dividend Yield | 0.59% |
| Annual Dividend | $6.00 |
| Next Earnings | February 05, 2026 05:00 AM ET |
Financial Ratios
| Gross Margin | 83.0% |
| Operating Margin | 43.9% |
| Net Margin | 31.0% |
| ROE | 102.3% |
| ROA | 16.0% |
| Debt/Equity | 1.79 |
| Current Ratio | 1.55 |
| Quick Ratio | 1.24 |
Balance Sheet
| Total Assets | $78.71B |
| Total Liabilities | $64.44B |
| Total Equity | $14.19B |
| Cash | $3.27B |
| Total Debt | $33.64B |
| Net Debt | $30.38B |
Income Statement
| Revenue | $45.04B |
| Gross Profit | $36.62B |
| Operating Income | $17.50B |
| Net Income | $10.59B |
| EBITDA | $15.23B |
| Revenue/Share | $66.25 |
Cash Flow
| Operating CF | $8.82B |
| CapEx | $8.40B |
| Free Cash Flow | $414.30M |
| Book Value/Share | $26.59 |
| Tangible Book/Share | $12.83 |
| Equity/Share | $26.53 |
Technical Indicators
| RSI (14) | 47.93 Neutral |
| MACD |
43.86
Signal: 54.44
|
| Volatility | 29.76% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +16.52% |
| Sharpe Ratio | 0.55 Fair |
| Volatility (Ann.) | 42.79% High Risk |
| LLY (1Y) | +16.52% |
| S&P 500 (1Y) | +11.86% |
| Alpha (Excess Return) | +4.66% |
Sector Comparison (Healthcare)
| Metric | LLY | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 49.55 | 30.89 | 85% |
| P/B Ratio | 38.08 | -1.21 | 98% |
| ROE (%) | 102.26% | 8.23% | 95% |
| Net Margin (%) | 30.99% | 9.69% | 93% |
| Stock Score | 580 | 503.0 | 85% |
| 1Y Return (%) | +16.52% | +4.22% | 78% |
Historical Price Analysis (Last 200 Days)
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1010.31 | $1045.51 | $1064.00 | $1055.10 | $905.62 | $811.25 | 47.93 | 43.86 | 29.76% | 3854911 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the LLY stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| LLY | Paychex (NASDAQ:PAYX) Stock Unloaded Sen. Shelley Moore Capito | Neutral | defenseworld.net | Read More |
| LLY | Meta Platforms (NASDAQ:META) Shares Acquired Sen. Shelley Moore Capito | Neutral | defenseworld.net | Read More |
| LLY | With Netflix's 10-for-1 Stock Split Complete, Here Are 3 Growth Stocks to Buy in December That Could Issue Stock Splits in 2026 | Positive | fool.com | Read More |
| LLY | Sen. Shelley Moore Capito Sells Lowe’s Companies, Inc. (NYSE:LOW) Stock | Neutral | defenseworld.net | Read More |
| LLY | Market Today: WBD Sale Bids, Meta Cuts, Apple Shake-Up | Neutral | gurufocus.com | Read More |
Company Information
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| CEO | David A. Ricks |
| Employees | 47000 |
| Country | US |
| IPO Date | 1972-06-01 |
| Exchange | NYSE |
| Website | https://www.lilly.com |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Similar Stocks (Healthcare - Drug Manufacturers - General)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category